ICOS

ICOS 詳細

英語名Inducible T-cell costimulator市販薬剤の数0
治験薬の数7ターゲットの別称Activation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
研究&開発段階Phase 2 Clinical
英語名Inducible T-cell costimulator
ターゲットの別称Activation-inducible lymphocyte immunomediatory molecule,Inducible T-cell costimulator,ICOS,CD278,AILIM,Inducible T Cell Costimulator,Inducible T-Cell Co-Stimulator,Inducible Costimulator,CD278 Antigen,CVID1,Inducible T-Cell Co-Stimulator Protein
市販薬剤の数0
治験薬の数7
研究&開発段階Phase 2 Clinical

ICOS 製品リスト

  • 属性

    Protein (6)

  • 製品ライブラリ

    オンライン (6)

  • Human (3)Mouse (2)Rat (1)

  • タグ

    His Tag & Avi Tag (1)Fc Tag (2)His Tag (3)

  • マーカー

    Biotin-labeled (1)Unconjugated (5)

ICOSバックグランド

Inducible T-cell costimulator (ICOS) is also known as Activation-inducible lymphocyte immunomediatory molecule (AILIM), CD278, which belongs to the CD28 family of immune costimulatory receptors consisting of CD28, CTLA-4 and PD-1. ICOS enhances all basic T-cell responses to a foreign antigen, namely proliferation, secretion of lymphokines, up-regulation of molecules that mediate cell-cell interaction, and effective help for antibody secretion by B-cells. CD278 / ICOS prevents the apoptosis of pre-activated T-cells and also plays a critical role in CD40-mediated class switching of immunoglobin isotypes.

ICOS分子の別称

ICOS,CD278,AILIM,Inducible T-cell costimulator

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
VopratelimabJTX-2011Phase 2 ClinicalJounce Therapeutics IncCarcinoma, Non-Small-Cell Lung; Neoplasms
詳細
FeladilimabGSK-609; GSK-3359609Phase 2 ClinicalGlaxosmithkline PlcHead and Neck Neoplasms; Multiple Myeloma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck
詳細
AcazicolceptALPN-101Phase 2 ClinicalAlpine Immune Sciences IncAutoimmune Diseases; Graft vs Host Disease; Inflammation; Lupus Erythematosus, Systemic; Lymphoproliferative Disorders
詳細
MEDI-570Phase 1 ClinicalJapan Tobacco (Hong Kong) LtdLupus Erythematosus, Systemic; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoma, T-Cell, Cutaneous; Mycosis Fungoides
詳細
IzuralimabXmAb-23104; XmAb-104Phase 1 ClinicalXencor IncCarcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms
詳細
Anti-ICOS (Bristol Myers Squibb)BMS-986226Phase 1 ClinicalBristol-Myers Squibb CompanyNeoplasms
詳細
anti-ICOS mAb (Bristol-Myers Squibb)Phase 1 ClinicalBristol-Myers Squibb CompanyNeoplasms; Solid tumours
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8